246 related articles for article (PubMed ID: 11222883)
21. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
22. The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.
van der Linde HJ; Van Deuren B; Somers Y; Loenders B; Towart R; Gallacher DJ
Br J Pharmacol; 2010 Dec; 161(7):1444-54. PubMed ID: 21054337
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.
Kimura K; Tabo M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):231-9. PubMed ID: 17785940
[TBL] [Abstract][Full Text] [Related]
24. Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic atrioventricular block canine model.
Izumi-Nakaseko H; Nakamura Y; Cao X; Wada T; Ando K; Sugiyama A
J Pharmacol Sci; 2016 Jun; 131(2):150-3. PubMed ID: 27262902
[TBL] [Abstract][Full Text] [Related]
25. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.
Varkevisser R; van der Heyden MA; Tieland RG; Beekman JD; Vos MA
Eur J Pharmacol; 2013 Nov; 720(1-3):49-54. PubMed ID: 24211677
[TBL] [Abstract][Full Text] [Related]
26. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades.
Chiba K; Sugiyama A; Satoh Y; Shiina H; Hashimoto K
Toxicol Appl Pharmacol; 2000 Nov; 169(1):8-16. PubMed ID: 11076691
[TBL] [Abstract][Full Text] [Related]
27. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome.
Vos MA; Gorenek B; Verduyn SC; van der Hulst FF; Leunissen JD; Dohmen L; Wellens HJ
Cardiovasc Res; 2000 Dec; 48(3):421-9. PubMed ID: 11090837
[TBL] [Abstract][Full Text] [Related]
28. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
[TBL] [Abstract][Full Text] [Related]
29. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
[TBL] [Abstract][Full Text] [Related]
30. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
31. Ventricular remodelling is a prerequisite for the induction of dofetilide-induced torsade de pointes arrhythmias in the anaesthetized, complete atrio-ventricular-block dog.
Dunnink A; van Opstal JM; Oosterhoff P; Winckels SK; Beekman JD; van der Nagel R; Cora Verduyn S; Vos MA
Europace; 2012 Mar; 14(3):431-6. PubMed ID: 21946817
[TBL] [Abstract][Full Text] [Related]
32. Experimental models of torsades de pointes.
Weissenburger J; Davy JM; Chézalviel F
Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
[TBL] [Abstract][Full Text] [Related]
33. Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.
Kambayashi R; Hagiwara-Nagasawa M; Goto A; Chiba K; Izumi-Nakaseko H; Naito AT; Matsumoto A; Sugiyama A
Heart Vessels; 2020 Apr; 35(4):593-602. PubMed ID: 31628538
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of isoproterenol on quinidine induced torsade de pointes.
Yamamoto H; Bando S; Nishikado A; Shinohara A; Hamai K; Yamamoto K; Ikefuji H; Ito S
Tokushima J Exp Med; 1991 Jun; 38(1-2):1-4. PubMed ID: 1948996
[TBL] [Abstract][Full Text] [Related]
35. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
36. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
Hashimoto K
Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of drug-induced QT prolongation in a halothane-anesthetized monkey model: effects of sotalol.
Ishizaka T; Yoshimatsu Y; Ozawa M; Kimotsuki T; Takasaki W; Manabe S; Yasuda M
J Pharmacol Toxicol Methods; 2009; 59(2):86-93. PubMed ID: 19367688
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of electromechanical window in anesthetized rabbit models of short QT and long QT syndromes.
Limprasutr V; Saengklub N; Meedech P; Kijtawornrat A; Hamlin RL
J Toxicol Sci; 2017; 42(5):579-587. PubMed ID: 28904293
[TBL] [Abstract][Full Text] [Related]
39. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes.
Kurita T; Ohe T; Marui N; Aihara N; Takaki H; Kamakura S; Matsuhisa M; Shimomura K
Am J Cardiol; 1992 Mar; 69(6):628-33. PubMed ID: 1536113
[TBL] [Abstract][Full Text] [Related]
40. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.
Vos MA; Verduyn SC; Gorgels AP; Lipcsei GC; Wellens HJ
Circulation; 1995 Feb; 91(3):864-72. PubMed ID: 7828315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
